13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study

Abstract The World Health Organization (WHO) prioritizes pneumococcal disease as a vaccine-preventable disease and recommends the inclusion of pneumococcal conjugate vaccines (PCV) in national immunization programs worldwide. However, PCV is not included in the National Immunization Program in China...

Full description

Bibliographic Details
Published in:	Infectious Diseases of Poverty
Main Authors:	Jiachen Wang, Yujue Wang, Ruoyu Xu, Ting Zhang, Yanyan Jiang, Yuanyuan Wang, Yi Wang, Yuanze Du, Wenxue Sun, Kai Deng, Weizhong Yang, Zengwu Wang, Luzhao Feng, Chunping Wang
Format:	Article
Language:	English
Published:	BMC 2023-12-01
Subjects:	Pneumococcal conjugate vaccine Pneumococcal disease Non-immunization program Vaccination Vaccine-preventable disease Vaccination strategy
Online Access:	https://doi.org/10.1186/s40249-023-01165-1

Similar Items

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
by: Earnshaw Stephanie R, et al.
Published: (2012-04-01)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021-03-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
by: Matthew Wasserman, et al.
Published: (2019-03-01)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019-03-01)

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
by: Jeffrey Vietri, et al.
Published: (2020-01-01)

Effect of different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in Vietnamese infants: results from a randomised controlled trialResearch in context
by: Heidi Smith-Vaughan, et al.
Published: (2023-03-01)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023-09-01)

A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine from Lower-Valent Pneumococcal Conjugate Vaccines in the French Pediatric Population
by: Stéphane Fiévez, et al.
Published: (2025-08-01)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
by: Ralf Rene Reinert, et al.
Published: (2012-06-01)

NEXT GENERATION PNEUMOCOCCAL CONJUGATE VACCINES EFFICACY AND EFFECTIVENESS IN DIFFERENT REGIONS OF THE WORLD
by: O. P. Kovtun, et al.
Published: (2014-01-01)

Bronchopulmonary Pathology Prevalence Among Premature infants and Estimation of Prophylactic Efficacy and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Premature infants with Bronchopulmonary Dysplasia
by: Vladislav V. Semerikov, et al.
Published: (2020-02-01)

Evolution, Clinical and Microbiological Characteristics of Invasive Pneumococcal Disease since the Introduction of the Pneumococcal Conjugate Vaccine 13-Valent in Adults over 18 Years Old
by: Juan Buades, et al.
Published: (2021-01-01)

Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine
by: Antoni Payeras, et al.
Published: (2015-04-01)

Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia
by: Vesa Lindström, et al.
Published: (2019-12-01)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)

Changes in Childhood Pneumonia Hospitalizations by Race and Sex Associated with Pneumococcal Conjugate Vaccines
by: Andrew D. Wiese, et al.
Published: (2016-06-01)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01)

Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment
by: Per Nived, et al.
Published: (2018-04-01)

The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma
by: Tatiana A. Kaliuzhnaia, et al.
Published: (2020-11-01)

Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea
by: Deborah Lehmann, et al.
Published: (2017-12-01)

Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States
by: Andrew D. Wiese, et al.
Published: (2019-04-01)

Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective
by: Xiuyan Li, et al.
Published: (2023-03-01)

Vaccinal Prevention of Lower Respiratory Tract Pneumococcal Disease in Adults Without Immunosuppression
by: I. A. Guchev
Published: (2020-05-01)

Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?
by: Cornelis H. van Werkhoven
Published: (2017-05-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
by: Sophie Warren, et al.
Published: (2023-08-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
by: Salil Bendre, et al.
Published: (2024-02-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
by: Salil Bendre, et al.
Published: (2024-02-01)

Vaccine Prevention of Pneumococcal Infection in Children
by: Alexander A. Baranov, et al.
Published: (2018-07-01)

Childhood invasive pneumococcal disease caused by non-7-valent pneumococcal vaccine (PCV7) serotypes under partial immunization in Taiwan
by: Ching-Fen Shen, et al.
Published: (2013-09-01)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
by: Michael W. Simon, et al.
Published: (2023-08-01)

Strategies for pneumococcal vaccination in older adults in the coming era
by: Kei Nakashima, et al.
Published: (2024-12-01)

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany
by: Felicitas Kühne, et al.
Published: (2023-12-01)

Effectiveness and impact of 7 and 13-valent pneumococcal conjugate vaccines in Chinese children: A systematic review and meta-analysis
by: Ran Peng, et al.
Published: (2025-12-01)

Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
by: Starla Hayward, et al.
Published: (2016-04-01)

Parental knowledge, attitudes and perception of pneumococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assessment
by: Choon How How, et al.
Published: (2016-09-01)

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
by: Lucila Rey-Ares, et al.
Published: (2024-05-01)

The New Era of Pneumococcal Vaccination in Adults: What Is Next?
by: Lale Ozisik
Published: (2025-05-01)